PMID- 15480522
OWN - NLM
STAT- MEDLINE
DCOM- 20050308
LR  - 20181113
IS  - 0020-9554 (Print)
IS  - 0020-9554 (Linking)
VI  - 45
IP  - 12
DP  - 2004 Dec
TI  - [Antireflux therapy--more than acid reduction?].
PG  - 1364-9
AB  - Because gastroesophageal reflux disease (GERD) is a motility disorder, acid 
      reduction with proton pump inhibitors (PPI) remains a symptomatic therapy with a 
      recurrence rate of over 90% after discontinuation of acid suppression. This 
      "therapeutic dilemma" becomes obvious in patients not responding sufficiently to 
      the conventional medication (therapy resistance, necessity of high PPI doses, 
      volume reflux). In this manuscript we analyze additional factors that may play a 
      role in the pathogenesis and interpretation of GERD. These additional factors 
      include gastroesophageal motility and esophageal barrier functions as well as 
      duodenogastroesophageal reflux and Helicobacter pylori infection. In addition, 
      basic problems in interpretation of therapeutic success such as placebo effect, 
      spontaneous remission of GERD, the role of sensory function and subjective 
      interpretation of symptoms and the overlap between physiological and pathological 
      reflux as well as functional disorders will be discussed.
FAU - Frieling, T
AU  - Frieling T
AD  - Medizinische Klinik II, Klinikum, Krefeld. Frieling@Klinikum-Krefeld.de
LA  - ger
PT  - English Abstract
PT  - Journal Article
TT  - Antirefluxtherapie--mehr als Saureblockade?
PL  - Germany
TA  - Internist (Berl)
JT  - Der Internist
JID - 0264620
RN  - 0 (Antacids)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
SB  - IM
MH  - Antacids/*administration & dosage
MH  - Anti-Bacterial Agents/administration & dosage
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Gastroesophageal Reflux/classification/*diagnosis/*therapy
MH  - Helicobacter Infections/complications/*drug therapy
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Practice Patterns, Physicians'
MH  - Risk Assessment/*methods
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2004/10/14 09:00
MHDA- 2005/03/09 09:00
CRDT- 2004/10/14 09:00
PHST- 2004/10/14 09:00 [pubmed]
PHST- 2005/03/09 09:00 [medline]
PHST- 2004/10/14 09:00 [entrez]
AID - 10.1007/s00108-004-1291-7 [doi]
PST - ppublish
SO  - Internist (Berl). 2004 Dec;45(12):1364-9. doi: 10.1007/s00108-004-1291-7.